Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 10/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | CLK3 | P49761 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854703 | 0.80 | PIM1 (0.41) | PIM1PIM2GPR119 | |
| SCHEMBL15854704 | 0.78 | SMN1; SMN2 (0.40) | GPR119 | |
| SCHEMBL15857915 | 0.75 | PIM1 (0.39) | PIM1PIM2GSK3BDYRK1ACLK2 | |
| SCHEMBL15854708 | 0.73 | PIM1 (0.61) | PIM1PIM2GSK3BDYRK1APIM3 | |
| SCHEMBL15854717 | 0.72 | PIM1 (0.60) | PIM1PIM2GSK3BDYRK1ACLK2 | |
| SCHEMBL12696026 | 0.65 | SMN1; SMN2 (0.43) | GPR119 | |
| SCHEMBL3683248 | 0.64 | SMN1; SMN2 (0.49) | GPR119 | |
| SCHEMBL12616697 | 0.63 | PIM1 (0.43) | PIM1PIM2GSK3BDYRK1ACLK2 | |
| SCHEMBL15854722 | 0.62 | PIM1 (0.62) | PIM1PIM2PIM3 | |
| SCHEMBL5244655 | 0.62 | SMN1; SMN2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885GSK3B 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.